This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Comparator drugs in statistical studies

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Comparator drugs and doses studied:

  • when a study has a comparator intervention against an active control, it is important that any comparisons that are made are fair
    • if a drug of interest was being compared with a control drug with respect to side effects then it would be an unfair comparison if a low dose of a drug of interest was compared with a high dose of a control drug because will have the effect of minimising the risk of side effects from the drug of interest and potentially maximising the harms seen with the control drug
    • if a drug of interest was compared with a control drug with respect to efficacy then an unfair comparison would be to compare a high dose of the drug of interest with a low dose of an active control drug - this would potentially maximise the efficacy of the drug of interest, but may minimise the efficacy of the control drug

Reference:

  1. MeReC Briefing (2005);30:1-7.
  2. Wiebe S. The principles of evidence-based medicine.Cephalalgia. 2000;20 Suppl 2:10-3.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.